Boehringer Ingelheim’s Nintedanib Shows Promise as a New Treatment for Malignant Pleural Mesothelioma
Boehringer Ingelheim’s Boehringer Ingelheim’s nintedanib has been granted PIM—Promising Innovative Medicine—status for the treatm…
Showing posts with label Mesothelioma. Show all posts
Showing posts with label Mesothelioma. Show all posts
Mesothelioma Survival Rate
Approximately 55 percent of mesothelioma patients live longer than 6 months, while roughly 35 percent live longer than one year. …
Mesothelioma Life Expectancy
Average life expectancy for mesothelioma patients is 12 to 21 months. How long a patient lives depends on several factors includi…
Subscribe to:
Posts (Atom)